Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
UNLOCK ASP3082 is an open label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to ASP3082 in metastatic/locally advanced Non-Samll-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC) with the presence of KRAS G12D mutation. The two cohorts of patients are the following : i. cohort NSCLC : patients with NSCLC with KRAS G12D mutation. ii. cohort PDAC : patients with PDAC with KRAS G12D mutation. Patients enrolled in the both cohorts will receive treatment with ASP3082 at the dose of 600 mg QW thereafter in a 21-day cycle. ASP3082 will be administred in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal. Tumor and blood samples will be collected at baseline, on-treatment and at the end of treatment visit only from patients who develop acquired resistance (acquired resistance is defined as a best response of CR, PR, or SD lasting more than 6 months, followed by PD).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony nowotwór płuc lub trzustki, który rozprzestrzenia się lub nie można go usunąć chirurgicznie
- •Obecność mutacji KRAS G12D potwierdzona badaniem guza lub krwi
- •Wcześniejsze leczenie chemioterapią lub innymi lekami (wymagania różnią się dla raka płuc i trzustki)
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (wynik ECOG 0-1)
- •Spodziewana długość życia co najmniej 3 miesiące
- •Co najmniej jeden widoczny guz na badaniach obrazowych
- •Guz dostępny do pobrania próbki tkanki i zgoda na biopsje
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Gustave Roussy
Villejuif, France
Institut Bergonié
Bordeaux, France
Centre Georges François Leclerc
Dijon, France
Institut Paoli Calmettes
Marseille, France
Hôpital Paris Saint-Joseph
Paris, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Trial contact
Yohann Loriot, MD, PhD
Chloé Serhal, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.